Narcolepsy Drugs Market Outlook:
Narcolepsy Drugs Market size was valued at USD 3.44 billion in 2025 and is expected to reach USD 8.29 billion by 2035, registering around 9.2% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of narcolepsy drugs is assessed at USD 3.72 billion.
The rising prevalence of narcolepsy globally owing to the stressful lifestyle along with the surge in consumption of alcohol and tobacco is one of the major factors estimated to drive the growth of the narcolepsy drugs. As per the report, approximately 20% of American adults smoke, while 64% use alcoholic beverages regularly.
The market growth is also attributed to the increasing demand for the latest therapies to cure the disorder and rising healthcare expenditure in various emerging economies. Further, there is a significant rise in the activities of research & development for the development of highly effective drugs on the back of unhealthy lifestyles of people. Between 2000 and 2018, global health expenditure increased steadily, reaching US$ 8.3 trillion, or 10% of the global GDP.
The creation of drugs for narcolepsy treatment has accelerated dramatically in recent years. Furthermore, administrations in nations including India and South Africa are encouraging the manufacturing of narcolepsy drugs due to the health benefits, which are projected to enhance the narcolepsy drugs industry growth throughout the forecast period.
Key Narcolepsy Drugs Market Insights Summary:
Regional Highlights:
- North America narcolepsy drugs market will dominate over 42.2% share by 2035, driven by rising prevalence of unhealthy lifestyles and technological advancements in diagnosis.
- Asia Pacific market will exhibit the fastest growth during the forecast timeline, driven by economic development, rising biotech investments, and increased adoption of better life standards.
Segment Insights:
- The central nervous system stimulants segment in the narcolepsy drugs market is projected to achieve a 35% share by 2035, attributed to their effectiveness in enhancing wakefulness in narcolepsy patients.
- The extreme sleepiness segment in the narcolepsy drugs market is projected to achieve the highest market share by 2035, driven by rising narcolepsy prevalence and increasing incidence of excessive daytime sleepiness.
Key Growth Trends:
- Rising Understanding Regarding Narcolepsy Disorders- The active involvement of various organizations globally to spread awareness related to the disorder and its symptoms is propelling the growth of the market. In addition, the rising knowledge regarding the treatment of narcolepsy and sleep disorders is leading to the rise in narcolepsy awareness programs. Further, increased concerns regarding the advantages of early diagnosis of narcolepsy drugs along with the promotions by governments to educate people & trained professionals regarding the disorder are accelerating the growth of the market. Therefore, these factors are estimated to drive the demand for the narcolepsy drugs market during the forecast period.Based on the study "Narcolepsy Presentation in Diverse Populations
- The growing incidence of narcolepsy around the world is projected to drive the industry ;A report released in January 2022 titled "Prevalence, incidence, and health care utilization of patients with narcolepsy
Major Challenges:
- Stringent Government Regulations
- Misdiagnosis or Postponed diagnosis
Key Players: Ligand Pharmaceuticals Incorporated, Jazz Pharmaceuticals Inc., Graymark Healthcare Inc., BIOPROJET, Novartis AG, Teva Pharmaceuticals Industries Ltd., Arena Pharmaceuticals Inc.
Global Narcolepsy Drugs Market Forecast and Regional Outlook:
Market Size & Growth Projections:
- 2025 Market Size: USD 3.44 billion
- 2026 Market Size: USD 3.72 billion
- Projected Market Size: USD 8.29 billion by 2035
- Growth Forecasts: 9.2% CAGR (2026-2035)
Key Regional Dynamics:
- Largest Region: North America (42.2% Share by 2035)
- Fastest Growing Region: Asia Pacific
- Dominating Countries: United States, China, Germany, Japan, India
- Emerging Countries: China, Japan, India, South Korea, Singapore
Last updated on : 8 September, 2025
Narcolepsy Drugs Market Growth Drivers and Challenges:
Growth Driver
- Rising Understanding Regarding Narcolepsy Disorders- The active involvement of various organizations globally to spread awareness related to the disorder and its symptoms is propelling the growth of the market. In addition, the rising knowledge regarding the treatment of narcolepsy and sleep disorders is leading to the rise in narcolepsy awareness programs. Further, increased concerns regarding the advantages of early diagnosis of narcolepsy drugs along with the promotions by governments to educate people & trained professionals regarding the disorder are accelerating the growth of the market. Therefore, these factors are estimated to drive the demand for the narcolepsy drugs market during the forecast period. Based on the study "Narcolepsy Presentation in Diverse Populations: an Update" released in November 2020, narcolepsy influences 0.87-1.21% of the worldwide population.
- Market participants' approval and introduction of new pharmaceuticals- Approval and launch of novel medications by market players are expected to play an important role in propelling market expansion in the next years. For instance, the FDA approved Avadel's New Drug Application (NDA) for FT218, an experimental, once-nightly composition of sodium oxybate employed for the treatment of high levels of drowsiness and cataplexy in people with narcolepsy, in March 2021.
- The growing incidence of narcolepsy around the world is projected to drive the industry- A report released in January 2022 titled "Prevalence, incidence, and health care utilization of patients with narcolepsy: a population-representative study" revealed that the early prevalence of narcolepsy in Europe is 0.64-1.37 per 100,000.
- Geriatric population growth worldwide- By 2030, one in every six persons on the globe is estimated to be 60 or older. The global population of individuals aged 60 and up will double (2.1 billion) by 2050.
- Extreme Psychological Stress- As of 2022, 19.86% of adults are suffering from a mental illness. The equivalent of roughly 50 million Americans. 4.91% have a severe mental disorder in America.
Challenges
- Stringent Government Regulations- Stringent government regulations regarding the agreement for narcolepsy drugs are identified as one of the factors expected to hamper the growth of the market over the forecast period.
- Risks Related to Narcolepsy Drugs- The ill effects of narcolepsy drugs along with the possibility of delay in diagnosis & treatment are anticipated to hinder the growth of the market. Further, a lack of acknowledgment among patients and medical care providers in developed & developing nations is restraining the market growth of narcolepsy drugs.
- Misdiagnosis or Postponed diagnosis
Narcolepsy Drugs Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2025 |
|
Forecast Period |
2026-2035 |
|
CAGR |
9.2% |
|
Base Year Market Size (2025) |
USD 3.44 billion |
|
Forecast Year Market Size (2035) |
USD 8.29 billion |
|
Regional Scope |
|
Narcolepsy Drugs Market Segmentation:
Disease Type Segment Analysis
Based on disease type, the market for narcolepsy drugs is segmented into extreme sleepiness, cataplexia, and others, out of which, extreme sleepiness is estimated to witness the highest market share owing to rising cases of narcolepsy worldwide along with the other disorders. During the projection period, the daytime extreme sleepiness segment is expected to hold the highest share of the market in the entire narcolepsy drugs market. The growth in narcolepsy prevalence increases the incidence of indications and other sleep disorders. Many patients with narcolepsy and other sleep disorders are more likely to experience this symptom, boosting the need for narcolepsy medicines. As additional firms enter the narcolepsy medicines industry, growth will be accelerated.
Therapeutics Type Segment Analysis
The global market of narcolepsy drugs is also segmented and analyzed for demand and supply by application into Central Nervous System Stimulants, tricyclic antidepressants, selective serotonin reuptake inhibitors, sodium oxybate, and others. Amongst these three segments, the central nervous system stimulants segment is expected to garner a significant share of around 35% in the year 2035. During the projected period, the Central Nervous System Stimulants segment is anticipated to take over the market. Therapeutics including modafinil, armodafinil, and additional central nerve stimulants for narcolepsy are focused on enhancing wakefulness in individuals with narcolepsy, based to an article published in CNS Drugs named "Recently Approved and Upcoming Treatments for Narcolepsy" in January 2021.
End-user Segment Analysis
Increasing studies about central nervous system stimulants is likely to fuel segment growth. Harmony Biosciences Holdings, Inc., a drug manufacturer devoted to creating and advertising cutting-edge treatments for individuals with rare neurological conditions, released an assessment of data of CNS drugs in December 2021 that assessed the period before the onset of response to pitolisant for EDS and cataplexy in grown-up patients with narcolepsy. Such research is projected to lead to the creation of innovative central nervous system stimulants, propelling the expansion of this segment.
Our in-depth analysis of the global market includes the following segments:
|
By Disease Type |
|
|
By Therapeutics Type |
|
|
By End Users |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Narcolepsy Drugs Market Regional Analysis:
North American Market Insights
North America region is poised to dominate around 42.2% market share by 2035. The market in North America is anticipated to dominate the market owing to the rising prevalence of unhealthy lifestyles along with the technological advancements for the diagnosis of disease. Further, an increase in the number of narcolepsy cases leading to the rising awareness for the treatment along with rising healthcare expenditure is driving the growth of the market. Narcolepsy impacts between 135,000 and 200,000 individuals across the United States, in accordance to a data sheet published in November 2021 by the National Institute of Neurological Disorders and Stroke. However, owing to this condition is often incorrectly diagnosed, the number could be substantially higher. As a result of the elevated incidence of narcolepsy in advanced nations such as the United States, the growing use of narcolepsy treatment is expected to drive market expansion in this area.
APAC Market Insights
The Asia Pacific region is estimated to witness the fastest growth rate on the back of economic development in major nations and rising investments in biotechnology sectors. In addition, the adoption of better standards of life and rising cases of sleep disorders is fostering the growth of the market. Japan has been identified as exhibiting a high frequency of narcolepsy among Asia Pacific countries. Governments in nations such as India are raising knowledge about the relevance of narcolepsy, which is projected to drive development in the narcolepsy drugs market over the forecast time frame. Moreover, the presence of established economic economies such as China and India is assisting in the development of healthcare facilities throughout the Asia-Pacific area. Furthermore, favorable government strategies in the Asia-Pacific region are encouraging the development of the narcolepsy drugs market. Other notable factors for expansion in this region's narcolepsy drugs market include multiple agreements between business entities and academic institutions in the region, along with an increase in the number of new products introduced, acquisitions, and product authorizations.
Europe Market Insights
The Europe region is estimated to foresee lucrative growth on the account of rising research & development initiatives for the progress in narcolepsy novel drugs. In 2022, Europe held the second-largest market share. The key reasons for this are improved medical services and the region's growing population. This sector is also being boosted by government activities about depressive illness and its consequences. Other positive contributing elements include having finances accessible for research and operations, the expansion of the large patient population, and the increase in the number of obese people. Furthermore, the presence of established economic nations in European regions including Italy, Germany, and France. According to Eurostat, more than half of people in Europe are obese.
Narcolepsy Drugs Market Players:
- Ligand Pharmaceuticals Incorporated
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Jazz Pharmaceuticals Inc.
- Graymark Healthcare Inc.
- BIOPROJET
- Novartis AG
- Teva Pharmaceuticals Industries Ltd.
- Arena Pharmaceuticals Inc.
Recent Developments
- Ligand Pharmaceuticals Incorporated and GSK declared the Licence Agreement and the global growth of their relationship. The development is expected to be fueled by Icagen's particle discovery method and expertise in small-molecule therapeutics addressing membrane proteins.
- Teva Pharmaceutical Industries Ltd. stated that they would spend USD 69 million to settle a Narcolepsy drug lawsuit in California. The reimbursement is expected to help the corporation in maintaining its monopoly in an industry where the rival corporation's Narcolepsy drugs will postpone their release by nearly six months.
- Report ID: 2767
- Published Date: Sep 08, 2025
- Report Format: PDF, PPT
- Get detailed insights on specific segments/region
- Inquire about report customization for your industry
- Learn about our special pricing for startups
- Request a demo of the report’s key findings
- Understand the report’s forecasting methodology
- Inquire about post-purchase support and updates
- Ask About Company-Level Intelligence Additions
Have specific data needs or budget constraints?
Inquiry Before BuyingFrequently Asked Questions (FAQ)
Narcolepsy Drugs Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
Copyright @ 2025 Research Nester. All Rights Reserved.
